Molnupiravir 200 mg Capsules

Description

Molnupiravir 200 mg Capsules – COVID-19 Antiviral Uses, Dosage, Side Effects & Full Guide
What is Molnupiravir?
Molnupiravir 200 mg Capsules is an oral antiviral medication used for the treatment of mild-to-moderate COVID-19 in adults who are at high risk of developing severe disease, including hospitalization or death. It is not a preventive drug or a cure for COVID-19 but helps reduce the severity and duration of the illness if taken early.
Strength: 200 mg per capsule
Brand Name: Lagevrio (by Merck & Ridgeback Biotherapeutics)
Drug Class: Antiviral (nucleoside analog)
Route: Oral (by mouth)
Mechanism of Action
Molnupiravir 200 mg Capsules is a prodrug, meaning it is converted into its active form inside the body. It transforms into N-hydroxycytidine (NHC), which is incorporated into the viral RNA during replication.
This incorporation leads to a high rate of mutations in the viral RNA.
The mutations cause “error catastrophe”, preventing the virus from replicating effectively.
It targets the SARS-CoV-2 RNA-dependent RNA polymerase (RdRp) enzyme, which is critical for viral genome replication.
Therapeutic Indication
Molnupiravir is indicated for:
The treatment of mild-to-moderate COVID-19 in adults (18 years and older)
Patients who have:
Tested positive for SARS-CoV-2
At least one risk factor for progression to severe disease (e.g., older age, diabetes, obesity, cardiovascular disease, chronic kidney/lung disease, immunocompromised state)
Must be started within 5 days of symptom onset for maximum effectiveness
Not approved for prevention of COVID-19 or use in patients younger than 18.
Dosage and Administration
Recommended Dose: 800 mg (four 200 mg capsules)
Frequency: Twice daily (every 12 hours)
Duration: 5 days (no more, no less)
Total capsules per course: 40
Instructions:
Swallow capsules whole with water.
Can be taken with or without food.
Do not open, crush, or chew capsules.
Efficacy
In clinical trials, Molnupiravir reduced the risk of hospitalization or death by around 30% compared to placebo.
Most effective when taken early (within 5 days) of symptoms appearing.
Side Effects
Most patients tolerate Molnupiravir well, but some may experience mild side effects:
Common Side Effects:
Nausea
Diarrhea
Dizziness
Headache
Less Common / Rare:
Rash
Vomiting
Temporary changes in liver enzyme levels
Warnings and Precautions
Pregnancy: Not recommended due to potential risk of fetal harm.
Women of childbearing potential should use reliable contraception during treatment and for 4 days after the last dose.
Male patients with partners of childbearing potential should use contraception during and for 3 months after treatment.
Breastfeeding: Avoid breastfeeding during treatment and for 4 days after the final dose.
Children and Adolescents: Not authorized for use in patients under 18 due to potential impact on bone and cartilage growth.
Drug Interactions
No significant drug interactions.
Does not require co-administration with a booster (like Ritonavir for Paxlovid).
Does not interact with cytochrome P450 enzymes.
Storage
Store at room temperature: 20°C to 25°C (68°F to 77°F)
Keep in original packaging.
Protect from moisture and direct sunlight.